Jazz Pharmaceuticals Plc (JAZZ) Stock Price & Analysis

Jazz Pharmaceuticals Plc (JAZZ) fell 0.30% to USD 246.81 as of September 8, 2026 at 06:23 UTC, according to Nexqual real-time market data.

JAZZ last closed at USD 246.81; the session ranged USD 244.75–248.97 on volume of 321,869 shares. Market capitalization is —, with a 52-week range of USD 123.88–266.38 (NMS). Source: Nexqual, September 8, 2026 at 06:23 UTC.

Key Statistics (as of September 8, 2026 at 06:23 UTC)

Technical Analysis (JAZZ)

Nexqual's technical model rates JAZZ "SELL" based on 1 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 06:23 UTC.

From Jazz Pharmaceuticals Plc's Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• Non-oxybate products intended for the treatment of EDS or cataplexy in narcolepsy or IH (Xywav is the first and only FDA-approved therapy to treat IH), including new market entrants, even if not directly competitive with Xywav or Xyrem, could have the effect of changing treatment regimens and payor or formulary coverage of Xywav or Xyrem in favor of other products, and indirectly materially and adversely affect sales of Xywav and Xyrem.
• We developed Rylaze to address the needs of patients and health care providers for an innovative, high-quality erwinia asparaginase with reliable supply.
• Their expertise, resilience, and commitment to patients enable us to advance our strategy with focus and confidence.
• Through direct input from employees, external insights and best practices, we developed our flexible working model; expanding the power of intentional collaboration and our ability to more effectively manage our global and highly distributed team workforce.

Partnerships

• In October 2020, we entered into an amendment to the license agreement with PharmaMar to expand our exclusive license to include rights to develop and commercialize Zepzelca in Canada.
• Under these amendments, we continue to have the right to a meaningful royalty from Hikma on net sales of the Hikma AG product throughout the extended Hikma AG period, which royalty rate was fixed through the end of 2025 and then subject to specified reductions as set forth in our agreement with Hikma.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:23 UTC. This page is informational and not investment advice.